Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Atossa Therapeutics, Inc.

Market Cap 1.58Cr 1.38Cr 1.28Cr 1.19Cr 2.24Cr 149.28Cr 2.28Cr 15Cr 5.93Cr 73Cr 5.92Cr 5.79Cr 254.57Cr P/E 2026 *
-0.42x
P/E 2027 * -0.53x
Enterprise Value 1.58Cr 1.38Cr 1.28Cr 1.19Cr 2.24Cr 149.28Cr 2.28Cr 15Cr 5.93Cr 73Cr 5.92Cr 5.79Cr 254.57Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+3.83%
1 week-14.41%
Current month-63.67%
1 month-61.62%
3 months-66.13%
6 months-81.48%
Current year-78.53%
1 week 1.78
Extreme 1.78
2.21
1 month 1.78
Extreme 1.78
5.3
Current year 1.78
Extreme 1.78
10.95
1 year 1.78
Extreme 1.78
19.35
3 years 1.78
Extreme 1.78
34.65
5 years 1.78
Extreme 1.78
147
10 years 1.78
Extreme 1.78
891
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
12/05
Ensisheim Partners LLC
OtherCompany 0 0%
12/05Free

Director

10,000 0.1161%
12/05Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+3.83%-14.41%-84.16%-85.73% 1.58Cr
+2.96%+4.08%-8.03%-2.24% 4.32TCr
+2.23%+8.26%+323.35%+564.22% 3.53TCr
+1.59%+4.63%+7.23%+54.02% 3.02TCr
+2.07%-4.40%+10.38%-19.99% 2.8TCr
-4.75%-8.29%+3.90%+13.88% 2.41TCr
+4.64%+3.20% - - 1.42TCr
+3.91%+2.57%+53.41%+111.95% 1.3TCr
+2.77%+2.93%+9.65%+11.90% 1.27TCr
+0.13%+3.97%+101.73%+91.70% 1.25TCr
Average +1.90%-2.92%+46.38%+82.19% 2.13TCr
Weighted average by Cap. +1.58%-0.72%+69.06%+120.35%

Financials

2026 *2027 *
Net sales - -
Net income -3.74Cr -3.28Cr -3.03Cr -2.83Cr -5.31Cr -354.22Cr -5.4Cr -36Cr -14Cr -173.8Cr -14Cr -14Cr -604.06Cr -3.93Cr -3.45Cr -3.18Cr -2.98Cr -5.58Cr -372.41Cr -5.68Cr -38Cr -15Cr -182.72Cr -15Cr -14Cr -635.07Cr
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
24/26/24 $1.900 +3.83% 5,34,686
22/26/22 $1.830 -8.96% 4,69,933
18/26/18 $2.010 +1.26% 1,93,503
17/26/17 $1.985 -10.59% 6,96,590
16/26/16 $2.220 -5.53% 3,10,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.830USD
Average target price
22.00USD
Spread / Average Target
+1,102.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!